一个协议来使用基因集富集分析以确定合适的动物模型转化型研究

Executive Industry Relevance

Selecting appropriate animal models remains a critical challenge in translational research, where model misalignment contributes to late-stage attrition. This protocol enables systematic evaluation of murine models using transcriptomic concordance with human disease data, reducing reliance on subjective gene filtering. By providing a standardized GSEA-based framework, it supports predictive confidence in model selection and informs go/no-go decisions early in discovery.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypothesis by assessing pathway-level concordance between human disease and animal model transcriptomes.
• Operational Value: Avoids biased interpretation from single-gene comparisons, reducing mechanistic ambiguity in target validation.
• Predictive Value: Enables data-driven prioritization of models with highest gain of information, supporting portfolio triage.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems by identifying models with conserved pathway regulation for downstream compound screening.
• Operational Value: Standardizes cross-study comparison through normalized enrichment scores and FDR values, enhancing reproducibility.
• Scalability: Supports inclusion of multiple human clinical studies and mouse models to identify optimal translational fit.

Translational & Preclinical Research

• Translational Continuity: Connects discovery through preclinical validation by identifying models with high correlation to human disease states.
• Risk-Adjusted Advancement: Uses gain of information and chi-squared testing to assess significance of model suitability, informing progression decisions.
• Biomarker Alignment: Facilitates identification of conserved pathways that may serve as translational biomarkers across species.

Pipeline & Workflow Integration

The method fits within the discovery continuum from target validation to preclinical model selection, enabling transcriptomic data to guide animal model choice before significant investment in screening or efficacy studies.

• Discovery Biology: Supports hypothesis testing by comparing whole-genome pathway activation or inhibition patterns between species.
• Screening: Enhances assay readiness by ensuring selected models reflect human disease biology, improving compound evaluation reliability.
• Analytics: Generates quantitative outputs (normalized enrichment score, FDR, gain of information) for objective cross-study comparison.
• Translational Research: Promotes continuity by selecting models with demonstrated pathway-level concordance to human conditions.
• Enterprise Reuse: Establishes a reusable bioinformatics capability applicable across disease areas and omics data types.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence in model selection, reducing false positives from inadequate biological representation.
• Operational Value: Promotes standardization and reproducibility in model evaluation across teams and sites.
• Strategic Value: Improves capital efficiency by minimizing investment in poorly predictive models.
• Portfolio Impact: Enables risk-adjusted prioritization of projects based on model suitability evidence.

Implementation Considerations

• Requires expertise in transcriptomic data analysis and GSEA software operation.
• Dependent on access to quality gene expression data from human disease studies and candidate animal models.
• Necessitates standardized data formatting, including gene symbol collapse and phenotype labeling.
• Involves cross-functional alignment between bioinformatics, pharmacology, and pathology teams for interpretation.
• Limited to retrospective analysis; cannot predict model suitability a priori without existing omics data.

Biopharma FAQs